Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia
- PMID: 24385809
- PMCID: PMC3878537
- DOI: 10.4274/Tjh.2012.0094
Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia
Abstract
Objective: Survival rates for childhood acute lymphoblastic leukemia (ALL) have significantly improved and late effects of therapy have been important in the follow-up of survivors. The objective of this study is to identify the endocrinological and cardiological late effects of ALL patients treated in our pediatric hematology unit.
Materials and methods: Patients treated for ALL with BFM protocols after at least 5 years of diagnosis and not relapsed were included in the study. Endocrinological late effects (growth failure, obesity, insulin resistance, dyslipidemia, thyroid gland disorders, osteopenia/osteoporosis, and pubertal disorders) and cardiological late effects were evaluated. The study group was evaluated with anthropometric measurements, body mass index, and laboratory testing of fasting glucose, insulin, serum lipids, thyroid functions, and bone mineral densities. Echocardiography and pulsed wave Doppler imaging were performed for analysis of cardiac functions.
Results: Of the 38 ALL survivors, at least 1 adverse event occurred in 23 (60%), with 8 of them (21%) having multiple problems. Six (16%) of the survivors were obese and 8 (21%) of them were overweight. Subjects who were overweight or obese at the time of diagnosis were more likely to be overweight or obese at last follow-up. Obesity was more frequently determined in patients who were younger than 6 years of age at the time of diagnosis. Insulin resistance was observed in 8 (21%) subjects. Insulin resistance was more frequently seen in subjects who had family history of type 2 diabetes mellitus. Hyperlipidemia was detected in 8 (21%) patients. Hypothyroidism or premature thelarche were detected in 2 children. Two survivors had osteopenia. Cardiovascular abnormalities occurred in one of the subjects with hypertension and cardiac diastolic dysfunction.
Conclusion: We point out the necessity of follow-up of these patients for endocrinological and cardiological late effects, since at least one adverse event occurred in most of our cases.
Conflict of interest: None declared.
Amaç: Akut lenfoblastik lösemili (ALL) çocuklarda sağkalım oranı belirgin düzelmiş ve izlemlerde geç yan etkiler açısından değerlendirilmeleri önemli hale gelmiştir. Bu çalışmanın amacı çocuk hematoloji kliniğimizde tedavisi tamamlanan akut lösemi olgularında uzun dönemde gelişebilecek endokrinolojik ve kardiyolojik geç etkilerin belirlenmesidir. Gereç ve Yöntemler: Lösemi tanısı aldığı tarihten itibaren en az beş yıl geçmiş, relaps gelişmemiş ve BFM protokolleri ile tedavi edilmiş hastalar endokrinolojik geç etkiler (boy kısalığı, obezite, insülin direnci, dislipidemi, tiroid hastalığı, osteopeni/osteoporoz, puberte sorunları) ve kardiyolojik geç etkiler açısından değerlendirildi. Çalışma grubunda antropometrik ölçümler, vücut kitle indeksi, açlık kan şekeri, insülin, serum lipid ve tiroid fonksiyon testleri ve kemik mineral dansiteleri araştırıldı. Kardiyak fonksiyonların analizinde ekokardiyografi ve pulsed Doppler görüntüleme kullanıldı.Bulgular: 38 olgudan 23’ünde (%60) en az bir, 8 olguda (%21) ise birden fazla geç etki olduğu görüldü. Altı olgunun (%16) fazla kilolu, 8’inin (%21) obez olduğu belirlendi. Tanı anında fazla kilolu ya da obez olanlarda ve tedavi bitiminde fazla kilolu ya da obez olanlarda son değerlendirmede obezite daha yüksek orandaydı. Tanı anında altı yaşın altında olanlarda obezite daha fazlaydı. Sekiz olguda (%21) insülin direnci vardı. Obez ya da fazla kilolu olanlarda ve ailede tip 2 DM öyküsü bulunanlarda insülin direnci daha yüksek oranda bulundu. Sekiz olguda (%21) hiperlipidemi saptandı. Hipotiroidi veya prematür telarş birer olguda, osteopeni 2 olguda görüldü. Kardiyolojik geç etki olarak bir olguda hipertansiyon ve hafif diastolik disfonksiyon olduğu belirlendi. Sonuç: Olguların çoğunda en az bir geç yan etki gözlendiğinden, bu çocukların endokrinolojik ve kardiyolojik geç etkiler açısından takip edilmelerinin gerekli olduğu ortaya çıkmaktadır .
Keywords: Cardiotoxicity; Chemotherapy; Endocrinology; Late effects; Leukemia; childhood.
Similar articles
-
Late effects in survivors of infant leukemia.Leukemia. 2000 Jul;14(7):1185-90. doi: 10.1038/sj.leu.2401818. Leukemia. 2000. PMID: 10914540
-
[Markers of metabolic syndrome and peptides regulating metabolism in survivors of childhood acute lymphoblastic leukemia].Przegl Lek. 2011;68(9):592-6. Przegl Lek. 2011. PMID: 22335007 Polish.
-
The Frequency of Metabolic Syndrome and Serum Osteopontin Levels in Survivors of Childhood Acute Lymphoblastic Leukemia.J Adolesc Young Adult Oncol. 2018 Aug;7(4):480-487. doi: 10.1089/jayao.2017.0129. Epub 2018 Mar 12. J Adolesc Young Adult Oncol. 2018. PMID: 29641359
-
Long-term effects on growth, development, and metabolism of ALL treatment in childhood.Expert Rev Endocrinol Metab. 2019 Jan;14(1):49-61. doi: 10.1080/17446651.2019.1561271. Epub 2018 Dec 31. Expert Rev Endocrinol Metab. 2019. PMID: 30596296 Review.
-
Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.Haematologica. 2000 Nov;85(11 Suppl):47-53. Haematologica. 2000. PMID: 11268324 Review.
Cited by
-
Metabolic differences among newborns born to mothers with a history of leukemia or lymphoma.J Matern Fetal Neonatal Med. 2022 Dec;35(25):6751-6758. doi: 10.1080/14767058.2021.1922378. Epub 2021 May 12. J Matern Fetal Neonatal Med. 2022. PMID: 33980115 Free PMC article.
-
Association Between Treatment of Childhood Cancer and Its Late Effects on Gonadal or Growth Function in Childhood Cancer Survivors: A Retrospective Observational Study.Cancer Med. 2025 Mar;14(6):e70805. doi: 10.1002/cam4.70805. Cancer Med. 2025. PMID: 40123531 Free PMC article.
-
Frequency of obesity and metabolic syndrome in childhood leukemia and lymphoma survivors.Diabetol Metab Syndr. 2022 Jan 24;14(1):16. doi: 10.1186/s13098-022-00790-4. Diabetol Metab Syndr. 2022. PMID: 35073984 Free PMC article.
References
-
- Tonorezos ES, Oeffinger KC. Survivorship after childhood, adolescent, and young adult cancer. Cancer J. 2008;14:388–395. - PubMed
-
- Lag R, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). SEER Cancer Statistics Review. Bethesda, National Cancer Institute; [Internet] http://seer.cancer.gov/csr/1975-2003 .
-
- Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–1582. - PubMed
-
- Geenen MM, Cardous-Ubbink MC, Kremer LC, Heinen RC, Jaspers MW, Koning CC, Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, Caron HN, Leeuwen FE., van Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297:2705–2715. - PubMed
-
- Langeveld NE, Ubbink MC, Last BF, Grootenhuis MA, Voûte PA, De Haan RJ. Educational achievement, employment and living situation in long-term young adult survivors of childhood cancer in the Netherlands. Psychooncology. 2003;12:213–225. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials